건선성 관절염(PsA) : 역학 예측(-2033년)

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy that may be progressive and can lead to severe joint damage and disability (Ogdie and Gelfand, 2011). The disease is considered rare in the general population, but PsA affects up to 30% of people with psoriasis (Ogdie and Gelfand, 2011; National Psoriasis Foundation, 2024). It is estimated that more than 85% of PsA cases are preceded by psoriasis, which can vary in form and duration; the remaining PsA cases are diagnosed simultaneously with psoriasis or in the absence of skin disease (Gottlieb et al., 2008; Wilson et al., 2009). PsA is a highly heterogeneous disease that may present with nonspecific symptoms, often making diagnosis difficult (Ogdie and Gelfand, 2011). General symptoms associated with PsA include generalized fatigue, tenderness in tendons, swollen fingers and toes, stiffness and pain in joints, conjunctivitis, and nail changes (National Psoriasis Foundation, 2024). Historically, diagnosing PsA has been difficult due to the limited recognition of the disease and the highly heterogeneous diagnostic criteria. However, the recently developed Classification of Psoriatic Arthritis (CASPAR) criteria have become the most accepted standard for diagnosing PsA.

In 2023, there were 45,580 diagnosed incident cases of PsA across the 7MM. The US accounted for the majority of these cases, with 22,124 diagnosed incident cases of PsA in men and women combined, ages 18 years and older. Japan accounted for the fewest cases in 2023, with 341 diagnosed incident cases of PsA. In 2023, there were 1,547,313 diagnosed prevalent cases of PsA across the 7MM. The US accounted for the majority of these cases, with 763,439 diagnosed prevalent cases of PsA in men and women combined, ages 18 years and older. Japan accounted for the fewest cases in 2023, with 12,063 diagnosed prevalent cases of PsA. Due to the methodology used by GlobalData to obtain primary market research (PMR) data, the main driver of growth in the diagnosed prevalent cases of PsA across the 7MM is the overall increase in the diagnosis rate of PsA. Additionally, GlobalData epidemiologists attribute the increase in the diagnosed incident cases and diagnosed prevalent cases of PsA in the 7MM to population dynamics in each market.

Scope

• This report provides an overview of the risk factors, comorbidities, and global and historical trends for PsA across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for diagnosed incident cases of PsA and a 10-year forecast of diagnosed prevalent cases of PsA segmented by sex and age (beginning at age 18 years and ending at ages 85 years or older) in these markets.
• This report also includes an assessment of PsA severity, an analysis of diagnosed prevalent cases by subtype based on the Moll and Wright Criteria, data on prevalent PsA cases with comorbidities, and a forecast of prevalent PsA cases with psoriasis.
• The epidemiology model will provide additional clinically relevant segmentations, including a forecast for the total prevalent cases (diagnosed and undiagnosed) of PsA.

Reasons to Buy

The Psoriatic arthritis (PsA) epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global PsA market.
• Quantify patient populations in the global PsA market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for PsA therapeutics in each of the markets covered.

Table of Contents

Table of Contents

• About GlobalData

1 Psoriatic Arthritis: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 Forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Diagnosed incident cases of PsA
  • 2.4.4 Diagnosed prevalent cases of PsA
  • 2.4.5 Diagnosed prevalent cases of PsA by type
  • 2.4.6 Diagnosed prevalent cases of PsA by severity
  • 2.4.7 Diagnosed prevalent cases of PsA with comorbidity
  • 2.4.8 Diagnosed prevalent cases of PsA with psoriasis
• 2.5 Epidemiological forecast for PsA (2023-33)
  • 2.5.1 Diagnosed incident cases of PsA
  • 2.5.2 Sex-specific diagnosed incident cases of PsA
  • 2.5.3 Age-specific diagnosed incident cases of PsA
  • 2.5.4 Diagnosed prevalent cases of PsA
  • 2.5.5 Sex-specific diagnosed prevalent cases of PsA
  • 2.5.6 Age-specific diagnosed prevalent cases of PsA
  • 2.5.7 Diagnosed prevalent cases by type
  • 2.5.8 Diagnosed prevalent cases by severity
  • 2.5.9 Diagnosed prevalent cases by comorbidity
  • 2.5.10 Diagnosed prevalent cases of PsA with psoriasis
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 Limitations of the analysis
  • 2.6.3 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 Primary research - prescriber survey
• 3.3 Primary market research - Key opinion leaders (KOLs) interviewed for this report
  • 3.3.1 KOLs
• 3.4 About the authors
  • 3.4.1 Epidemiologist
  • 3.4.2 Reviewers
  • 3.4.3 Vice President of Disease Intelligence and Epidemiology
  • 3.4.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
• Contact Us